Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug. [PDF]
Conklin LS +31 more
europepmc +1 more source
Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. [PDF]
Gerber PA +11 more
europepmc +1 more source
Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes. [PDF]
Hoffman EP +9 more
europepmc +1 more source
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. [PDF]
Heier CR +11 more
europepmc +1 more source
VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis. [PDF]
Dillingham BC +12 more
europepmc +1 more source
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993). [PDF]
Atherton PJ +6 more
europepmc +1 more source
Inhibition of chlorine-induced pulmonary inflammation and edema by mometasone and budesonide. [PDF]
Chen J, Mo Y, Schlueter CF, Hoyle GW.
europepmc +1 more source
Suppression of cytokine release by fluticasone furoate vs. mometasone furoate in human nasal tissue ex-vivo. [PDF]
Zhang N +7 more
europepmc +1 more source

